NOVRAD
LOE ApproachingNDAORALCAPSULE
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVRAD is an oral small-molecule capsule approved by Eli Lilly in 1962 with an unknown mechanism of action and indication profile. The specific therapeutic area and patient population remain undocumented in available data.
LOE Approaching
Product is in LOE-approaching phase with moderate competitive pressure (30), indicating a mature asset likely operating with a stable but reduced commercial footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NOVRAD currently shows zero linked job openings, reflecting its mature, late-lifecycle stage. Career opportunities on this product are limited; roles available would focus on maintenance, compliance, and managed decline rather than growth or innovation.
Field SalesBrand Manager
Worked on NOVRAD at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.